Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island

NCT04310917 | Unknown

• 1 other identifier: 2020/CHU/01
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Cardiovascular disease (CVD) is the second leading cause of death in France and the leading cause of death on Reunion Island. Some modifiable risk factors for cardiovascular diseases are well identified and can be easily modulated, in particular by hygiene and dietetic measures (tobacco, sedentary lifestyle). Other risk factors such as high blood pressure, diabetes or dyslipidemia can also be pharmacologically modulated. On the other hand, there is a cardiovascular risk factor that we do not know how to modulate: a high level of lipoprotein (a) (Lp (a)), whose regulation remains largely unknown. High plasma levels of Lipoprotein (a) remain a major risk for the development of cardiovascular disease and its clinical complications, which no drug can currently reduce. Understanding the biological and genetic determinants modulating Lp (a) levels remains a major challenge for treating subjects with hyper Lp (a). Several individuals and possibly Reunion families have been detected as having abnormally high rates of apo (a) Thanks to the link between cardiovascular clinical picture, Lp (a) concentration and other biological markers, the study should allow a better understanding of the mechanisms underlying the cardiovascular risk in order to offer advice. prevention and care of at-risk subjects screened; or even avenues for adapted genetic counseling (DNA sequencing). At the genetic level, several hypotheses could be explored making it possible to link the expression of the apo (a) protein to the genotype, in particular the presence of mutations in the gene, in the promoter region, polymorphisms, or epistatic regulation.

Conditions

Cardiovascular Disease

Outcome Measures

Primary Outcomes (1)

• Carry out a family screening of the plasma Lp (a) level

  Carry out a family screening of the plasma Lp (a) level around index cases followed or directed towards Reunion University Hospital (index case = Lp (a) rate\> 200nmol / L)

  at inclusion

Study Arms (1)

Lipoprotein a level

OTHER

blood lipoprotein (a) test

Other: blood lipoprotein (a) test

Interventions

blood lipoprotein (a) test OTHER

research specific blood sample

Lipoprotein a level

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient with Lp (a)\> 200 nmol / L OR member of family of a patient with Lp (a)\> 200 nmol / L
• be affiliated or beneficiary of a social security scheme
• signed consent

You may not qualify if:

• Refusal to participate

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Réunion: lead

Study Sites (1)

Centre Hospitalier Universitaire de la Réunion

Saint-Denis, 97400, France

RECRUITING

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

• Ilya KHANTALIN, PH

  CHU de la Réunion

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lucie AUZANNEAU

CONTACT

0262359949; lucie.auzanneau@chu-reunion.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 13, 2020
• First Posted: March 17, 2020
• Study Start: September 19, 2020
• Primary Completion: March 1, 2023
• Study Completion: June 1, 2023
• Last Updated: August 30, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)